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Abstract
Background: Ginsenoside Rg3, a saponin extracted from ginseng, inhibits angiogenesis. The
combination of low-dose chemotherapy and anti-angiogenic inhibitors suppresses growth of
experimental tumors more effectively than conventional therapy or anti-angiogenic agent alone.
The present study was designed to evaluate the efficacy of low-dose gemcitabine combined with
ginsenoside Rg3 on angiogenesis and growth of established Lewis lung carcinoma in mice.
Methods: C57L/6 mice implanted with Lewis lung carcinoma were randomized into the control,
ginsenoside Rg3, gemcitabine and combination group. The quality of life and survival of mice were
recorded. Tumor volume, inhibitive rate and necrosis rate were estimated. Necrosis of tumor and
signals of blood flow as well as dynamic parameters of arterial blood flow in tumors such as peak
systolic velocity (PSV) and resistive index (RI) were detected by color Doppler ultrasound. In
addition, expression of vascular endothelial cell growth factor (VEGF) and CD31 were observed
by immunohistochemstry, and microvessel density (MVD) of the tumor tissues was assessed by
CD31 immunohistochemical analysis.
Results: Quality of life of mice in the ginsenoside Rg3 and combination group were better than in
the control and gemcitabine group. Combined therapy with ginsenoside Rg3 and gemcitabine not
only enhanced efficacy on suppression of tumor growth and prolongation of the survival, but also
increased necrosis rate of tumor significantly. In addition, the combination treatment could
obviously decrease VEGF expression and MVD as well as signals of blood flow and PSV in tumors.
Conclusion: Ginsenoside Rg3 combined with gemcitabine may significantly inhibit angiogenesis
and growth of lung cancer and improve survival and quality of life of tumor-bearing mice. The
combination of chemotherapy and anti-angiogenic drugs may be an innovative and promising
therapeutic strategy in the experimental treatment of human lung cancer.
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Background
It is well established that the growth and progression of
most solid cancers are angiogenesis – dependent; thus
anti-angiogenic therapy is one of the most promising
approaches for the treatment of cancers [1-3]. Folkman
predicted that anti-angiogenesis would become the fourth
treatment modality for cancer, besides surgery, chemo-
therapy, and radiation. More than 20 anti-angiogenic
agents such as TNP-470, thalidomide, endostatin and
angiostatin are subject to different phases of clinical trials
[2]. Avastin (Bevacizumab) was approved by FDA in 2004
for the treatment of colorectal cancer [4]. Anti-angiogenic
agents bear potential as a treatment of cancer.
Nowadays, efforts have been directed toward discovering
of new anti-angiogenic agents. Ginsenoside Rg3, a
saponin, extracted from ginseng, is a very powerful ang-
iogenic inhibitor [2,5,6]. Some experiment findings indi-
cate that ginsenoside Rg3 exhibits anticancer activity in
vitro and in vivo models as a relatively safe medicine [5].
However, emerging data suggest that cancer therapy tar-
geting only the tumor-existing vessels or tumor angiogen-
esis may not eradicate the tumor completely. Thus, the
efficacy of anti-angiogenesis alone may be limited in
advanced tumors [7].
Lung cancer is the leading cause of cancer death world-
wide and gemcitabine is a nucleoside analog, accepted as
a first-line chemotherapeutic agent for the disease. How-
ever, conventional chemotherapy schemes for the treat-
ment of cancer mostly produce a limited improvement,
associated with considerable side-effects and acquired
drug resistance [5,8-10]. Results from animal models sug-
gest that chronic administration of low doses of chemo-
therapy has an effect on the tumor and other
compartments, mainly the vasculature [11].
In recent years there has been increasing interest in com-
bining radiation or chemotherapy with angiogenesis
inhibitors for tumor suppression – the combination may
be more appropriate to produce improved efficacy and
reduced toxicity by transcending each limitation [2].
Some results from animal models have suggested that the
combination of low-dose chemotherapy with anti-angio-
genesis therapy for solid tumors can suppress tumor
growth more effectively than conventional chemotherapy
or anti-angiogenic therapy alone [9,12-15]. However, the
effectiveness of combination treatment of ginsenoside
Rg3 and low-dose gemcitabine on lung cancer remains
unclear. The present study was designed to evaluate the
efficacy of ginsenoside Rg3 combined with low-dose gem-
citabine on angiogenesis and growth of established Lewis
lung carcinoma in mice.
Methods
Materials
A group of female C57BL/6 mice (6–8 week age) weighing
between 18 g and 20 g were purchased from the Experi-
mental Animal Center of Chinese Academy of Sciences.
Mice were housed under pathogen-free conditions, and
fed with animal chow and water ad libitum. Lewis lung
carcinoma cell line was obtained from Cancer Research
Institution of Sichuan University. Gemcitabine was sup-
plied by Eli Lilly Company (USA). Ginsenoside Rg3 was
extracted from northeast China's ginseng, and purity quo-
tient was not less than 99.5%, and provided by YaTai
Pharmaceutical Company (China). Mouse monoclonal
antibody for vascular endothelial growth factor (VEGF)
was purchased from Santa Cruz (USA). Mouse mono-
clonal antibody for CD31 and LSAB kit were purchased
from Dako (Japan).
Cell culture
Human Lewis lung carcinoma cells were cultured in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum plus ampicillin and strepto-
mycin routinely, and incubated in 5% CO2 at 37°C.
Design of animal experiments
All animal procedures were approved by the Animal Care
and Scientific Committee of Sichuan University. The
tumor tissues from Lewis lung carcinoma mice were tritu-
rated and prepared into cell suspensions (dilution 1:5
with normal saline). The cells harvested from xenografts
were adjusted to a concentration of 1×107/ml, and 0.2 ml
cell suspensions were injected subcutaneously into the
armpit of right anterior superior limbs of female C57BL/6
mice. Seven days later, when the tumors were palpable,
the mice were randomized into the following four groups
(10 mice per group): a gemcitabine group injected intra-
peritoneally with gemcitabine on every 3rd day (10 mg/
kg) in a total of 6 treatments; a ginsenoside Rg3 group,
which received ginsenoside Rg3 by gastric perfusion daily
(20 mg/kg) for 18 consecutive days; a combination group
(gemcitabine plus ginsenoside Rg3) treated with gemcit-
abine and ginsenoside Rg3 on the same schedule as
above, and a control group injected with normal saline
subcutaneously. All treatments lasted for 18 days.
Tumor growth, side effects and quality of life of mice
The length and width of tumor were callipered every 4
days for tumor growth, and tumor volume (TV) was esti-
mated using the formula: TV (mm3) = (width2 × length)/
2. During the experiment period, side effects such as
weight loss, change in behavior and feeding, reaction to
stimulation, ruffling of fur and psychosis (distress) were
observed. When a mouse died, the size of tumor and the
number of living days were recorded.BMC Cancer 2009, 9:250 http://www.biomedcentral.com/1471-2407/9/250
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Inhibitive rate of tumor
18 days after the treatment, the remaining mice in all
groups underwent color Doppler before they were sacri-
ficed and then the size and weight of tumors were
recorded. Inhibitive rate of tumor was calculated using the
formula [16]: inhibitive rate of tumor (%) = (1- average
tumor weight in treated group/average tumor weight in
control) × 100%.
Necrosis rate of tumor
Necrosis rate of tumor was assessed using pathological
slices way [8,17]. Necrosis rate of tumor was determined
using the following formula: necrosis rate of tumor =
tumor necrosis area/whole tumor area × 100% (tumor
necrosis area = the largest diameter × the smallest diame-
ter of the tumor necrosis area; whole tumor area = the larg-
est diameter × the smallest diameter of the tumor area)
Observation of necrosis of tumor
The size, shape of tumor, ultrasonic echo from tumor
inner to known liquefied tumor and necrotic tissues were
detected under the two-dimensional ultrasound by color
Doppler (ACUSON1228ST) with 5 MHz frequency.
Detection of dynamic parameters of arterial blood flow 
intumor by color Doppler flow imaging (CDFI)
Signals of blood flow in tumor were evaluated by CDFI
with color Doppler at 5 MHz. Briefly, the tumor was care-
fully scanned form different angles with attention to vas-
cularity and intratumoral and peritumoral arterial flow
signals. Vascularity could be arterial or venous. When the
margins of the tumor were clearly seen, the location of the
largest arterial vessel relative to the tumor was deter-
mined. Pulsed Doppler sample volume was located on
the largest arterial vessel and the angle of the transducer
was adjusted manually to obtain the maximum amplitude
and frequency shift (Doppler angle < 60°). Arterial blood
stream frequency spectrum was captured and stored for
later analysis of parameters.
Signals of blood flow in tumor of CDFI were classified
into four grades based on the criteria of Adler [18]: 0, no
blood flow signals detected within the tumor; I, minimal
blood flow (one or two dot-like or a thin- and short-like
blood flow signals detected within the tumor); II, moder-
ate blood flow (up to three dot-like blood flow signals or
one longer blood flow signals detected within the tumor);
and III, abundant blood flow (more than five dot-like
blood flow signals or two longer blood flow signals
detected within the tumor).
Artery parameters in tumor such as peak systolic velocity
(PSV, cm/s), end diastolic velocity (EDV, cm/s) and resis-
tive index (RI, RI = PSV-EDV/PSV) were evaluated by
blood stream frequency spectrum. A mean value for each
parameter of intratumoral and peritumoral arterial blood
flow was obtained from at least three different measure-
ments.
Immunohistochemical detection of CD31 and VEGF
Tumor tissues were fixed immediately in 10% buffered
formalin phosphate and embedded in paraffin. Immuno-
histochemical staining was performed using a labeled
streptavidin-biotin method. Briefly, the dewaxed, rehy-
drated sections (5 μm) were treated with 0.3% hydrogen
peroxide in methanol for 30 min to block endogenous
peroxidase activity and then washed three times with 0.01
M phosphate buffered saline (PBS, pH 7.2). The sections
were permeabilized with ethylene diamine tetraacetic acid
(EDTA) buffer solution (pH 9.0) for 15 min with micro-
wave. Nonspecific binding was blocked with 2% normal
goat serum at room temperature for 15 min followed by
treatment with primary antibody at 37°C for 2 h (anti-
CD31 diluted for 1:100 and anti-VEGF diluted for 1:50).
After washed by PBS, sections were then incubated with
biotin labeled secondary antibody diluted for 1:100 at
37°C for 30 min and washed with PBS. Peroxidase conju-
gated streptavidin was added for 20 min and then washed
with PBS. Finally, sections were developed with 3, 3-
diaminobenzidine and hydrogen peroxide and counter-
stained with hematoxylin. For the negative control, PBS
was used instead of primary antibody. The sections were
analyzed by light microscopy.
VEGF staining was considered positive if unequivocal yel-
low brown staining was seen in the tumor cell cytoplasm,
and the immunoreactivity was scored semiquantitatively
as the intensity of the immunoreactive reaction and posi-
tive percent of tumor cells [16]. The intensity of the
immunoreactive reaction were graded as 0, no immunore-
activity; 1, weak intensity; 2, moderate intensity; 3, strong
intensity. Positive percent were graded as 0 to 4 score (0,
< 10%; 1, 10%–24%; 2, 25%–49%; 3, 50%–75%; 4, ≥
75%). After adding the scores of intensity and positive
percent, we rescaled to score 0 to 1 as negative (-), 2 to 3
as weak expression (1+), 3 to 4 as moderate expression
(2+) and above 5 as strong expression (3+).
Detection of microvessel density (MVD)
MVD was assessed by immunohistochemical analysis
with antibodies to the endothelial marker CD31 and
determined according to the method of Weidner and col-
leagues [19]. Briefly, the immunostained sections were
initially screened at low magnifications (40× and 100×) to
identify hot spots, which are the areas of highest neovas-
cularization. Any yellow brown stained endothelial cell or
endothelial cell cluster that was clearly separate from adja-
cent microvessels, tumor cells, and other connective tissue
elements was considered a single, countable microvessel.
Within the hot spot area, the stained microvessels wereBMC Cancer 2009, 9:250 http://www.biomedcentral.com/1471-2407/9/250
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counted in a single high-power (200×) field, and the aver-
age vessel count in 3 hot spots was considered the value of
MVD. All counts were performed by three investigators in
a blinded manner. Microvessel counts were compared
between the observers and discrepant results were reas-
sessed. The consensus was used as the final score for anal-
ysis.
Statistical analysis
TV, necrosis rate of tumor, MVD, PSV and RI were ana-
lyzed by one-way analysis of variance (ANOVA), followed
by the Student's t test. Data of inhibitive rate of tumor was
analyzed by Chi-square test. Survival curves were con-
structed according to the Kaplan-Meier method and statis-
tical significance was determined by the log-rank test.
VEGF and grade of CDFI were analyzed by Kruskal-Wallis
test. All statistical analyses were performed using SPSS
11.5 software package. All P values were two-sided and P
< 0.05 was considered as the significant level of difference.
Results
Tumor volume, inhibitive rate and survival rate
The treatment began on the 7th day after the mice were
transplanted with tumor cells. Treatment with gemcitab-
ine or ginsenoside Rg3 alone showed an appreciable
decrease in tumor volume compared with that of the con-
trols during treatment period. Remarkably, the combina-
tion group showed enhanced efficacy on tumor volume
suppression (Figure 1A). In addition, inhibitive rate of
tumor in the combination group was significantly higher
than that of the ginsenoside Rg3 group. Inhibitive rate of
tumor in the combination group also was higher than that
in the gemcitabine group, but the difference did not reach
statistical significance (P > 0.05) (Figure 1B).
18 days after the treatments, the number of living mice in
the control, gemcitabine, ginsenoside Rg3 and combina-
tion group were 6, 7, 9 and 10, respectively. The mice died
from tumor deterioration and side effects of therapy,
excluding improper experimental manipulation by mice
anatomy. The cumulative survival rate was 60%, 70%,
90% and 100%, respectively. Combined therapy with gin-
senoside Rg3 and gemcitabine resulted in prolonged sur-
vival compared with the control or gemcitabine group (P
< 0.05) (Figure 1C).
Tumor necrosis and necrosis rate of tumor
Tumor necrosis was detected by color Doppler before the
mouse was killed. As shown in Figure 2, there were obvi-
ously multi-local and larger areas of tumor necrosis in the
combination (Figure 2D) and ginsenoside Rg3 group (Fig-
ure 2C), and only smaller areas of tumor necrosis detected
in the gemcitabine (Figure 2B) and control group (Figure
2A). The necrosis rate of tumor in both the combination
Effect of ginsenoside Rg3 and gemcitabine on tumor growth and survival Figure 1
Effect of ginsenoside Rg3 and gemcitabine on tumor growth and survival. A: tumor growth curve; B: inhibitive rate 
of tumor; C: survival curve. Tumor volume (TV) (mm3) = (width2 × length)/2. Inhibitive rate of tumor (%) = (1- average tumor 
weight in treated group/average tumor weight in control) × 100%. Survival curves were constructed according to the Kaplan-
Meier method and statistical significance was determined by the log-rank test. 1: control group; 2: gemcitabine group; 3: ginse-
noside Rg3 group; 4: combination group. ▲P < 0.05 vs control group; P < 0.05 vs gemcitabine group; ■P < 0.05 vs ginsenoside 
Rg3 group. Combined therapy with ginsenoside Rg3 and gemcitabine enhanced efficacy on suppression of tumor growth and 
prolongation of the survival.
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and the ginsenoside Rg3 group was evidently higher than
that in the gemcitabine and control group (P < 0.05). The
necrosis rate in the combination group also was higher
than that in the ginsenoside Rg3 group (30.7% vs 24.5%),
however, without significant difference (P > 0.05) (Figure
2E).
Signals of blood flow in tumor
The number of arterial blood flow frequency spectrum
detected in the control, gemcitabine, ginsenoside Rg3 and
combination group were 6, 5, 7 and 6, respectively. Detec-
tion rates of arterial flow in the control, gemcitabine, gin-
senoside Rg3 and combination group were 100% (6/6),
71.4% (5/7), 77.8% (7/9) and 60% (6/10), respectively.
As shown in Figure 3, color Doppler flow imaging showed
that signals of blood flow in tumor were the worst in the
combination group and the best in the control group. The
signals of blood flow were mainly level 0-I (9/10) in the
combination group, while mostly at level III (4/6) or level
II (1/6) in the control group. The signals were intermedi-
ate in the gemcitabine and ginsenoside Rg3 group.
Dynamic parameters of arterial blood flow in tumor
PSV in tumor in the combination group decreased signif-
icantly compared with the other three groups (P < 0.05).
No statistically significant changes in RI were found
among groups (P > 0.05) (Figure 4).
MVD and VEGF expression
MVD was determined by counting the number of the
microvessels per high-power field (hpf) in the section
with an antibody reactive to CD31 (Figure 5A). Compared
with the control group, MVD value in the ginsenoside
Rg3, gemcitabine and combination group decreased obvi-
ously, especially in the combination group (P < 0.05)
(Figure 5B). There was positive expression of VEGF in the
cytoplasm of some tumor cells. The VEGF expression in
the ginsenoside Rg3, gemcitabine and combination group
was lower than that in the control group (P < 0.05), and
VEGF expression in the combination group was lower
than in the gemcitabine and ginsenoside Rg3 group (P <
0.05) (Figure 6). The results indicated that ginsenoside
Rg3 inhibited tumor angiogenesis and its anti-angiogenic
effect was further improved when combined with gemcit-
abine.
Side effects and quality of life of mice
There were no significant abnormalities in psychosis, sta-
tus of activity, reaction to stimulation, loss of weight,
appetite or depilation of mice in the ginsenoside Rg3
group though it was not the case in the combination, con-
trol or gemcitabine group. The quality of life of mice in
the ginsenoside Rg3 group was the best and the worst was
found in the gemcitabine group. The side effects were
reduced and quality of life improved in the combination
group compared with the gemcitabine group. The find-
Effect of ginsenoside Rg3 and gemcitabine on necrosis of tumor Figure 2
Effect of ginsenoside Rg3 and gemcitabine on necrosis of tumor. Multi-local and larger areas of tumor necrosis 
(arrow) in the combination (Figure 2D) and ginsenoside Rg3 group (Figure 2C), and only smaller areas of tumor necrosis 
detected in the gemcitabine (Figure 2B) and control group (Figure 2A) detected by color Doppler ultrasound. E: necrosis rate 
of tumor (necrosis rate of tumor = tumor necrosis area/whole tumor area × 100%). Necrosis rate of tumor was assessed using 
pathological slices way. ▲P < 0.05 vs control group; ■P < 0.05 vs gemcitabine group.
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ings indicated that ginsenoside Rg3 might potently
decrease side effects of therapy and improve quality of life
of tumor-bearing mice.
Discussion
Anti-angiogenic therapy for cancer is aimed to produce a
'dormant' state in which tumor cell proliferation and
tumor expansion are stalled by inhibiting tumor-related
angiogenesis, thus depriving the tumors of essential nutri-
ents and oxygen [20]. Anti-angiogenic therapy has shown
both protective and therapeutic anti-tumor effects. How-
ever, the fact that angiogenesis inhibitors do not act
directly on the tumor cells suggests that complete eradica-
tion of a tumor is unlikely with the anti-angiogenic treat-
ment alone [8,10].
Gemcitabine, 2-2-difluoro-2-deoxycytidine (dFdC), is
one of the most effective chemotherapy medicaments
against lung cancer. dFdC is a deoxycytidine analog that
inhibits DNA synthesis. After taken up by cells, dFdC is
phosphorylated to its active metabolites, which inhibits
DNA chain elongation, leading to DNA fragmentation
and cell death [8,10,21]. In addition, dFdC is also capable
of inhibiting ribonucleotide reductase, an enzyme with a
key role in DNA repair procedures [7,22]. Chemotherapy
is one of the mainstays for cancer therapy. However, drug
resistance and relatively strong toxic side effects (some-
times even unbearable) complicate treatment [8]. Thus, it
is conceivable that anti-angiogenic combined with chem-
otherapy may exert greater effect on tumor growth, even
eliminating tumor.
At present, anti-cancer drugs are moving toward natural
chemical compounds from animals and plants. Given
advances in Chinese herbal medicine, researchers are
becoming increasingly interested in detecting anti-tumor
components in Chinese herbal medicine. Ginsenoside
Rg3 is an effective chemical trace component extracted
from ginseng with C42H72O13 framework and 784 Da
molecular weight [5]. Ginsenoside Rg3 has been shown to
Observation of blood flow in tumors by color Doppler flow imaging (CDFI) Figure 3
Observation of blood flow in tumors by color Doppler flow imaging (CDFI). A: more than five dot-like blood flow 
signals and three club-like blood flow signals (arrow) detected in tumors in the control group; B: dot- and club-like blood flow 
(arrow) in tumors in the gemcitabine group; C: a short-like blood flow (arrow) in tumors in the ginsenoside Rg3 group; D: a 
thin- and short-like blood flow (arrow) in tumors in the combination group. E: levels of signals of blood flow. Signals of blood 
flow in tumors of CDFI were classified into four grades: 0, no blood flow signals detected within the tumor; I, minimal blood 
flow (one or two dot-like or a thin- and short-like blood flow signals detected within the tumor); II, moderate blood flow (up 
to three dot-like blood flow signals or one longer blood flow signals detected within the tumor); and III, abundant blood flow 
(more than five dot-like blood flow signals or two longer blood flow signals detected within the tumor).
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exhibit anti-cancer activity, and the anti-tumor effect has
been attributed to the actions of inhibiting growth, inva-
sion, metastasis of various tumors and neovascularization
[2,5].
In the present study, gemcitabine combined with ginseno-
side Rg3 showed a significant tumor growth inhibition
than ginsenoside Rg3 alone. The data suggest that the
combination of low-dose chemotherapy with anti-ang-
iogenic therapy for lung cancer can suppress tumor
growth more effectively than anti-angiogenic therapy
alone. Furthermore, the inhibitive rate of tumor of the
combination therapy group was higher than gemcitabine
group without statistical significance. It seems that the
effect of anti-tumor growth in the combination group is
not superior to chemotherapy alone. However, data from
color Doppler show that combination therapy led to
multi-local, larger areas of tumor necrosis, while only
smaller areas of tumor necrosis presented in the gemcitab-
ine group. The necrosis rate of tumor in both the combi-
nation and ginsenoside Rg3 group was evidently higher
than that in the gemcitabine group. The findings suggest
that ginsenoside Rg3 or combined with gemcitabine can
promote tumor necrosis more effectively than chemother-
apy alone. Morioka et al. reported that in the therapy of
mouse chondrosarcoma, combination therapy of ang-
iogenic inhibitor PRP-B and chemotherapeutic drug ET-
743 caused significantlygreater necrosis relative to any
individual treatment, although tumor volume measure-
ments did not parallel the necrosis values, who consid-
ered the curative effect in the combination group to be
superior to the single drug group [8].
Tumor volume and necrosis rate of tumor are usually used
to evaluate treatment effect of chemotherapy. In fact,
tumor volume may actually increase with increasing
tumor necrosis [8,23]. Thus, estimating the tumor volume
alone is no longer an adequate parameter when evaluat-
ing therapy [24]. Some researchers consider that tumor
necrosis rather than tumor volume is used as a criterion
for determining treatment effect of chemotherapeutic
agents [8,25].
Anti-angiogenic therapy is initially active on capillary for-
mation. Subsequent hypoxia induces tissue degeneration
and tumor cell eradication [24]. The higher necrosis rate
of tumor observed with ginsenoside Rg3 treatment alone
and combination treatment as compared with gemcitab-
ine treatment alone may be due to the effect of ginseno-
side Rg3. Ginsenoside Rg3, an angiogenic inhibitor,
restrains tumor-dependent angiogenesis and then aggra-
vates ischemia and hypoxemia of tumor tissues.
Changes of dynamic parameters of arterial blood flow in tumors by color Doppler flow imaging Figure 4
Changes of dynamic parameters of arterial blood flow in tumors by color Doppler flow imaging. PSV: peak systo-
lic velocity; RI: resistive index, RI = PSV-EDV/PSV (EDV: end diastolic velocity). P < 0.05 vs control group; P < 0.05 vs gem-
citabine group; ■P < 0.05 vs ginsenoside Rg3 group.
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Angiogenesis plays an important role in both tumor
growth and metastasis [26]. Angiogenesis is tightly regu-
lated by pro-angiogenic and anti-endothelial growth fac-
tors. VEGF is one of the most essential pro-angiogenic
growth factors [27], and it also appears to be critical in the
angiogenic process [28]. MVD is accepted as a standard
indicator of angiogenesis [24] and VEGF expression is
strictly correlated with MVD [29,30]. In the present study,
MVD in the ginsenoside Rg3, gemcitabine and combina-
tion group decreased obviously, especially in the combi-
nation group. In addition, VEGF protein expression in
tumors was also consistent with that of MVD, which were
in agreement with the findings of Xu TM, et al [6,31,32].
Our data indicated that ginsenoside Rg3 and gemcitabine
reinforced each other's inhibitory effect of angiogenesis by
decreasing MVD value and VEGF expression.
Doppler sonography is noninvasive, easy to perform,
which can give important information about tumor ves-
sels [24] and the hemodynamic characteristics of tumors
[24,31,32] and monitor the responses to anti-tumor ther-
apy [31]. In the present study, color Doppler flow imaging
showed that signals of blood flow and PSV in the combi-
nation group decreased significantly compared with the
other three groups.
Altogether, data above indicate that ginsenoside Rg3 and
low-dose gemcitabine may potentiate each other's antitu-
mor activities. The mechanism responsible for the interac-
tion between gemcitabine and low-dose chemotherapy
remains unclear. On one hand, the mechanism for the
anti-tumor effect of ginsenoside Rg3 is associated with
inducing apoptosis, regulating cell cycle, blocking angio-
genesis, and inhibiting metastasis [5,10]. On the other
hand, being a cytotoxic agent, gemcitabine could interfere
with DNA synthesis and induce DNA breakage, thus caus-
ing tumor cell apoptosis [10,33-35]. It has been reported
that gemcitabine could result in downregulation of
tumor-cell-produced VEGF by inducing tumor cell apop-
tosis [10,36]. In addition, some results of recent experi-
mental studies have suggested that frequent
administration of certain cytotoxic agents at low doses
increases the anti-angiogenic activity of the drugs
[9,10,37]. The above effects may contribute to the syner-
gistic inhibition of tumor angiogenesis and growth. How-
ever, the exact mechanisms need further study.
Immunohistochemical staining of CD31 and microvessel density (MVD) Figure 5
Immunohistochemical staining of CD31 and microvessel density (MVD). A: CD31 (200×). The blood vessels in 
tumor tissues were stained in yellow brown. a: control group; b: gemcitabine group; c: ginsenoside Rg3 group; d: combination 
group. B: MVD. MVD was determined by counting the number of microvessels per high-power field (hpf) in the section with an 
antibody reactive to CD31. P < 0.05 vs control group; P < 0.05 vs gemcitabine group; ■P < 0.05 vs ginsenoside Rg3 group.
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Ginseng is one of the most popular herbal medicines and
has been used to proactively promote health, vitality, and
longevity in Asian countries for more than 2000 years
[2,38,39]. In recent years, ginseng has gained significant
popularity in western societies [5,40], and has been
included in the Pharmacopoeias of several western coun-
tries such as Germany, France, Austria, and the United
Kingdom [38,41]. Many studies have reported that gin-
seng promotes a wide range of pharmacologic activities in
the immune, cardiovascular, endocrine, and central nerv-
ous systems [38,42,43]. Several clinical trials have demon-
strated that ginseng could improve overall quality of life
in healthy volunteers or patients with certain diseases,
such as diabetes [38,41]. Recently, a large, population-
based cohort study (1,455 breast cancer patients) showed
that ginseng use after cancer diagnosis, particularly cur-
rent use, was positively associated with quality of life
scores, with the strongest effect in the psychological and
social well-being domains [38].
Ginsenosides are the major active components of ginseng,
which have been shown to have a variety of beneficial
effects, including immunomodulatory [2], antioxidant
[44], anti-stress [2], anti-inflammatory [44], anti-aging
activities [2], and anti-fatigue [2], et al. In addition, ginse-
noside Rg3 is a relatively safe and effective medicine [5].
Some results demonstrated that ginsenoside Rg3 not only
had no side effects on marrow, heart, lung, liver, kidney,
and the nervous system [5], but also could improve the
living quality of mice with tumor [6,30]. In this study, gin-
senoside Rg3 combined with gemcitabine demonstrated
enhanced efficacy on the prolongation of survival. In
addition, quality of life of mice in the ginsenoside Rg3
and combination group were better than in the control
and gemcitabine group. To date, the exact mechanism of
ginsenoside Rg3 improving quality of life remains
unclear. We believe that the effects may be attributed to its
wide spectrum of medicinal effects, which endow ginse-
noside Rg3's special predominance differing from other
angiogenic inhibitors. In 2000, Rg3 appeared in the mar-
ket as a new anti-cancer drug called "Shen-Yi Capsule" in
China. Now, Ginsenoside Rg3 has been applied into clin-
ical therapy as a Class I new drug in China [2].
Effect of ginsenoside Rg3 and gemcitabine on VEGF expression of tumors Figure 6
Effect of ginsenoside Rg3 and gemcitabine on VEGF expression of tumors. A: Immunohistochemical staining of 
VEGF (200×). a: control group; b: gemcitabine group; c: ginsenoside Rg3 group; d: combination group. B: VEGF score. VEGF 
staining was scored semiquantitatively as the intensity of the immunoreactive reaction and positive percent of tumor cells. 
Score 0 to 1 was as negative (-), 2 to 3 as weak expression (1+), 3 to 4 as moderate expression (2+) and above 5 as strong 
expression (3+). 1: control group; 2: gemcitabine group; 3: ginsenoside Rg3 group; 4: combination group.
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Conclusion
The present study suggests that ginsenoside Rg3 com-
bined with gemcitabine may significantly inhibit angio-
genesis and growth of lung cancer and improve survival
and quality of life of tumor-bearing mice. The combina-
tion of chemotherapy and anti-angiogenic drugs may be
an innovative and promising therapeutic strategy for the
experimental treatment of human lung cancer.
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